Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study
Background and Aims: Given advances in antiretroviral therapy (ART), some people with HIV are transitioned to non-tenofovir-containing ART; the implications for people with HIV-hepatitis B virus (HBV) are unknown. We characterized HBV-related outcomes in people with HIV-HBV coinfection while not tak...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Virus Eradication |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664024001882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585120320585728 |
|---|---|
| author | Amir M. Mohareb Patrick Miailhes Julie Bottero Caroline Lascoux-Combe Julie Chas Sarah Maylin Audrey Gabassi Hayette Rougier Emily P. Hyle Constance Delaugerre Karine Lacombe Anders Boyd |
| author_facet | Amir M. Mohareb Patrick Miailhes Julie Bottero Caroline Lascoux-Combe Julie Chas Sarah Maylin Audrey Gabassi Hayette Rougier Emily P. Hyle Constance Delaugerre Karine Lacombe Anders Boyd |
| author_sort | Amir M. Mohareb |
| collection | DOAJ |
| description | Background and Aims: Given advances in antiretroviral therapy (ART), some people with HIV are transitioned to non-tenofovir-containing ART; the implications for people with HIV-hepatitis B virus (HBV) are unknown. We characterized HBV-related outcomes in people with HIV-HBV coinfection while not taking tenofovir-containing ART. Methods: We analyzed participants from the French HIV-HBV Cohort Study in three treatment groups: (1) continuous tenofovir; (2) discontinued tenofovir; (3) never initiated tenofovir. We examined virological and clinical characteristics during follow-up. We assessed determinants of HBV DNA >2000 IU/mL and alanine aminotransferase (ALT) >2x upper limit of normal separately while participants were off tenofovir using univariable logistic regression with generalized estimating equations. Results: Among 192 participants, 161 (83.9 %) were on continuous tenofovir, 22 (11.5 %) discontinued tenofovir, and 9 (4.7 %) never initiated tenofovir during a median follow-up of 14.5 years (IQR = 10.5–14.8). The median proportion of within-participant visits with undetectable HBV DNA was 96.0 % (IQR = 75.0–100) in the continuous group, 100 % (IQR = 84.0–100) in the discontinued tenofovir group (while off tenofovir), and 100 % (IQR = 95.2–100) in the never initiated tenofovir group. Determinants of HBV DNA >2000 IU/mL while people were off tenofovir were detectable HIV RNA (p = 0.041), lower CD4+ T-cell count (p = 0.027), HBeAg positive serology (p = 0.004) and positive hepatitis D serology (p = 0.001). ALT elevation was associated with positive hepatitis C antibody serology (p = 0.012). Conclusions: This proof-of-concept study shows that selected people with HIV-HBV coinfection may not lose virologic control of HBV when off tenofovir. HBV virologic activity while off tenofovir may be more closely associated with uncontrolled HIV infection and positive HBeAg serology. |
| format | Article |
| id | doaj-art-2f6b6c42a456435dae3f47a656036e64 |
| institution | Kabale University |
| issn | 2055-6640 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj-art-2f6b6c42a456435dae3f47a656036e642025-01-27T04:21:50ZengElsevierJournal of Virus Eradication2055-66402024-12-01104100574Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort studyAmir M. Mohareb0Patrick Miailhes1Julie Bottero2Caroline Lascoux-Combe3Julie Chas4Sarah Maylin5Audrey Gabassi6Hayette Rougier7Emily P. Hyle8Constance Delaugerre9Karine Lacombe10Anders Boyd11Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USAHôpital de Fleyriat, Service de Maladies Infectieuses et Tropicales, Bourg en Bresse, 01012, FranceEtablissement Public National de Santé de Fresnes, 94260, Fresnes, France; APHP, Hôpital Bicêtre, Service de Maladies Infectieuses, 94270, Kremlin-Bicêtre, FranceAPHP, Hôpital Saint-Louis, Service de Maladies Infectieuses, Paris, F75010, FranceAPHP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, F75020, FranceAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, F75010, FranceAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, F75010, France; Université de Paris, INSERM U944, Institut de Recherche Saint-Louis, F75010, Paris, FranceIMEA, Institut de Médecine et d’Epidémiologie Appliquée, Paris, F75018, FranceMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA; Harvard Center for AIDS Research, Boston, USAAPHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, F75010, France; Université de Paris, INSERM U944, Institut de Recherche Saint-Louis, F75010, Paris, FranceSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, F75012, France; APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, FranceAPHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, France; Corresponding author. Stichting hiv monitoring, Amsterdam UMC, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.Background and Aims: Given advances in antiretroviral therapy (ART), some people with HIV are transitioned to non-tenofovir-containing ART; the implications for people with HIV-hepatitis B virus (HBV) are unknown. We characterized HBV-related outcomes in people with HIV-HBV coinfection while not taking tenofovir-containing ART. Methods: We analyzed participants from the French HIV-HBV Cohort Study in three treatment groups: (1) continuous tenofovir; (2) discontinued tenofovir; (3) never initiated tenofovir. We examined virological and clinical characteristics during follow-up. We assessed determinants of HBV DNA >2000 IU/mL and alanine aminotransferase (ALT) >2x upper limit of normal separately while participants were off tenofovir using univariable logistic regression with generalized estimating equations. Results: Among 192 participants, 161 (83.9 %) were on continuous tenofovir, 22 (11.5 %) discontinued tenofovir, and 9 (4.7 %) never initiated tenofovir during a median follow-up of 14.5 years (IQR = 10.5–14.8). The median proportion of within-participant visits with undetectable HBV DNA was 96.0 % (IQR = 75.0–100) in the continuous group, 100 % (IQR = 84.0–100) in the discontinued tenofovir group (while off tenofovir), and 100 % (IQR = 95.2–100) in the never initiated tenofovir group. Determinants of HBV DNA >2000 IU/mL while people were off tenofovir were detectable HIV RNA (p = 0.041), lower CD4+ T-cell count (p = 0.027), HBeAg positive serology (p = 0.004) and positive hepatitis D serology (p = 0.001). ALT elevation was associated with positive hepatitis C antibody serology (p = 0.012). Conclusions: This proof-of-concept study shows that selected people with HIV-HBV coinfection may not lose virologic control of HBV when off tenofovir. HBV virologic activity while off tenofovir may be more closely associated with uncontrolled HIV infection and positive HBeAg serology.http://www.sciencedirect.com/science/article/pii/S2055664024001882Hepatitis BHIVVirus replicationTenofovirTreatment simplification |
| spellingShingle | Amir M. Mohareb Patrick Miailhes Julie Bottero Caroline Lascoux-Combe Julie Chas Sarah Maylin Audrey Gabassi Hayette Rougier Emily P. Hyle Constance Delaugerre Karine Lacombe Anders Boyd Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study Journal of Virus Eradication Hepatitis B HIV Virus replication Tenofovir Treatment simplification |
| title | Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study |
| title_full | Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study |
| title_fullStr | Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study |
| title_full_unstemmed | Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study |
| title_short | Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study |
| title_sort | virological and serological outcomes in people with hiv hbv coinfection who had discontinued tenofovir containing antiretroviral therapy results from a prospective cohort study |
| topic | Hepatitis B HIV Virus replication Tenofovir Treatment simplification |
| url | http://www.sciencedirect.com/science/article/pii/S2055664024001882 |
| work_keys_str_mv | AT amirmmohareb virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT patrickmiailhes virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT juliebottero virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT carolinelascouxcombe virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT juliechas virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT sarahmaylin virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT audreygabassi virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT hayetterougier virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT emilyphyle virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT constancedelaugerre virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT karinelacombe virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy AT andersboyd virologicalandserologicaloutcomesinpeoplewithhivhbvcoinfectionwhohaddiscontinuedtenofovircontainingantiretroviraltherapyresultsfromaprospectivecohortstudy |